In the second-line setting, pemetrexed improves survival in nonsquamous NSCLC compared with docetaxel, and erlotinib has shown a survival benefit compared with best supportive care in patients who ...

Top-line data from the SERENA-6 trial showed that camizestrant reduced the risk of disease progression or death compared to the standard-of-care regimen in previously untreated patients with HR ...

non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending its use into the first-line setting. Transaction Details Jazz's tender offer for all ...

LBBP is defined as capturing the left bundle branch (LBB) trunk or its fascicles, whereas capturing only the left septal ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

The first is the upcoming ASCENT-03 trial (NCT05382299) in first-line patients with metastatic TNBC who are not candidates for PD-L1-based therapy. Second is the pivotal ASCENT-05 trial (NCT05633654) ...